STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

EPIX Pharmaceuticals, Inc.

Form 4

November 12, 2004

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

OMB 3235-0287 Number:

January 31, Expires: 2005

burden hours per response... 0.5

Estimated average

Check this box if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

See Instruction

1(b).

a 10b5-1 **Trading** Plan)

(Print or Type Responses)

1. Name and Address of Reporting Person * CARPENTER ALAN P JR			2. Issuer Name and Ticker or Trading					5. Relationship of Reporting Person(s) to Issuer			
CARILIVILA ALAIVI JA			•	Symbol EPIX Pharmaceuticals, Inc. [EPIX]				(Check all applicable)			
(Last)	(First)	(Middle)	3. Date of Earliest Transaction					(Check an applicable)			
			(Month/Day/Year)					Director	10%	Owner	
C/O EPIX PHARMACEUTICALS,			11/10/2004					_X_ Officer (give title Other (specify			
INC., 161 F						below) V.P. of Legal & Govt. Affairs					
(Street)			4. If Ame	4. If Amendment, Date Original				6. Individual or Joint/Group Filing(Check			
			Filed(Month/Day/Year)					Applicable Line)			
								_X_ Form filed by	1 0		
CAMBRIDGE, MA 02138								Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative	Secur	ities Acq	uired, Disposed o	f, or Beneficial	ly Owned	
1.Title of	2. Transaction Da	te 2A. Dee	med	3.	4. Securi	ties A	cquired	5. Amount of	6. Ownership	7. Nature of	
Security	(Month/Day/Year)	) Execution	Execution Date, if		ate, if Transaction(A) or Disposed of (D)						
(Instr. 3) any		Code (Instr. 3, 4 and 5)				5)	Beneficially (D) or Benef				
		(Month/	Day/Year)	(Instr. 8)				Owned Following	Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
								Reported	(111511. 1)	(Histi: 1)	
						(A)		Transaction(s)			
				Code V	Amount		Price	(Instr. 3 and 4)			
Common	11/10/2004			M	2,000	٨	\$	8,000	D		
Stock	11/10/2004			IVI	2,000	A	8.781	8,000	D		
Common											
Stock (Sale											
Pursuant to				(2)							
2 10h5_1	11/10/2004			S(2)	2,000	D	\$ 16.7	6,000	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of **SEC 1474** information contained in this form are not (9-02)

#### Edgar Filing: EPIX Pharmaceuticals, Inc. - Form 4

required to respond unless the form displays a currently valid OMB control number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 1 9 (
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to buy)	\$ 8.781	11/10/2004		M		2,000	02/22/2003	02/22/2011	Common Stock	2,000	

#### **Reporting Owners**

Reporting Owner Name / Address	Relationships						
. 9	Director	10% Owner	Officer	Other			
CARPENTER ALAN P JR			V.P. of				
C/O EPIX PHARMACEUTICALS, INC.			Legal &				
161 FIRST STREET			Govt.				
CAMBRIDGE, MA 02138			Affairs				

## **Signatures**

Paula Valencia-Galbraith, Attorney-in-Fact

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- From February 22, 2001 grant of 200,000 options to purchase common stock of which 75,250 options have been exercised and 123,750 options are remaining. 45,750 options of the remaining 123,750 options are currently exercisable and the remaining 80,000 options vest in two equal installments beginning on February 22, 2005.
- (2) Sale Pursuant to a 10b5-1 Trading Plan

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2